Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease

Published:2021-10-27 Issue:11 Volume:15 Page:17016-17046
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Tang Rou¹²^ORCID,Li Rui²,Li He¹^ORCID,Ma Xiao-Lei²,Du Peng¹²,Yu Xiao-You²,Ren Ling¹²,Wang Lu-Lu¹²,Zheng Wen-Sheng¹

Affiliation:

1. Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

2. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

Funder

Ministry of Science and Technology of the People's Republic of China

Chinese Academy of Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

General Physics and Astronomy,General Engineering,General Materials Science

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.1c02158

Reference300 articles.

1. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

2. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement